+44 20 8123 2220
info@marketpublishers.com

Alpha-1 Antitrypsin Deficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

https://marketpublishers.com/r/A706494D522CEN.html
Date: May 2024
Pages: 133
Price: US$ 6,499.00 (Single User License)
ID: A706494D522CEN

Abstracts

The 7 major alpha-1 antitrypsin deficiency markets reached a value of US$ 1.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.9 Million by 2034, exhibiting a growth rate (CAGR) of 9.83% during 2024-2034.

The alpha-1 antitrypsin deficiency market has been comprehensively analyzed in IMARC's new report titled "Alpha-1 Antitrypsin Deficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Alpha-1 antitrypsin deficiency (AATD) refers to a genetic disorder characterized by decreased levels or malfunctioning of the alpha-1 antitrypsin protein, which leads to a higher risk of developing lung and liver diseases. The most common manifestation is lung disorder, which can include chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, etc. Individuals with AATD may experience various symptoms, such as shortness of breath, wheezing, coughing, recurring respiratory infections, etc. In some cases, the ailment can also affect the liver, leading to liver diseases characterized by jaundice, fatigue, and abdominal swelling. The diagnosis of alpha-1 antitrypsin deficiency typically consists of a combination of clinical evaluation, laboratory investigations, and genetic analysis. Numerous laboratory tests, such as alpha-1 antitrypsin protein level measurement and protease inhibitor activity assays, can provide initial indications of deficiency. A confirmatory diagnosis includes genetic testing to identify mutations in the SERPINA1 gene, which encodes the alpha-1 antitrypsin protein. Additionally, various other procedures, such as lung function tests, imaging studies, liver function tests, etc., may be performed to assess the extent of lung or liver involvement.

The rising cases of genetic mutations that result in the production of abnormal protein

+44 20 8123 2220
info@marketpublishers.com

variants, thereby leading to an imbalance of protease enzymes in the body, are primarily driving the alpha-1 antitrypsin deficiency market. Apart from this, the widespread adoption of augmentation therapy, which involves regular intravenous infusions of purified alpha-1 antitrypsin protein, to protect the lungs from damage caused by an imbalance of protease enzymes, is acting as another significant growth-inducing factor. Additionally, the increasing utilization of pulmonary rehabilitation programs involving exercises and breathing techniques for improving lung function, developing physical endurance, and optimizing overall respiratory health is also augmenting the market growth. Moreover, several key players are making significant investments in R&D activities to introduce disease-modifying therapies that focus on reducing the accumulation of misfolded alpha-1 antitrypsin protein within cells and enhancing the clearance of abnormal protein aggregates. This, in turn, is creating a positive outlook for the market. Besides this, the emerging popularity of expanded genetic panels since they allow the identification of rare or novel mutations in addition to the commonly screened mutations, thereby improving the accuracy of genetic diagnosis, is expected to drive the alpha-1 antitrypsin deficiency market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the alpha-1 antitrypsin deficiency market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for alpha-1 antitrypsin deficiency and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the alpha-1 antitrypsin deficiency market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

+44 20 8123 2220
info@marketpublishers.com

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the alpha-1 antitrypsin deficiency market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the alpha-1 antitrypsin deficiency market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current alpha-1 antitrypsin deficiency marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of

+44 20 8123 2220
info@marketpublishers.com

marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the alpha-1 antitrypsin deficiency market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the alpha-1 antitrypsin deficiency market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the alpha-1 antitrypsin deficiency market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of alpha-1 antitrypsin deficiency across the seven major markets?
What is the number of prevalent cases (2018-2034) of alpha-1 antitrypsin deficiency by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of alpha-1 antitrypsin deficiency by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of alpha-1 antitrypsin deficiency by type across the seven major markets?
How many patients are diagnosed (2018-2034) with alpha-1 antitrypsin deficiency across the seven major markets?
What is the size of the alpha-1 antitrypsin deficiency patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of alpha-1 antitrypsin deficiency?
What will be the growth rate of patients across the seven major markets?

Alpha-1 Antitrypsin Deficiency: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

+44 20 8123 2220
info@marketpublishers.com

What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for alpha-1 antitrypsin deficiency drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the alpha-1 antitrypsin deficiency market?
What are the key regulatory events related to the alpha-1 antitrypsin deficiency market?
What is the structure of clinical trial landscape by status related to the alpha-1 antitrypsin deficiency market?
What is the structure of clinical trial landscape by phase related to the alpha-1 antitrypsin deficiency market?
What is the structure of clinical trial landscape by route of administration related to the alpha-1 antitrypsin deficiency market?

+44 20 8123 2220
info@marketpublishers.com

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 ALPHA-1 ANTITRYPSIN DEFICIENCY - INTRODUCTION

4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 ALPHA-1 ANTITRYPSIN DEFICIENCY - DISEASE OVERVIEW

5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 PATIENT JOURNEY

7 ALPHA-1 ANTITRYPSIN DEFICIENCY - EPIDEMIOLOGY AND PATIENT POPULATION

+44 20 8123 2220
info@marketpublishers.com

7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)

+44 20 8123 2220
info@marketpublishers.com

7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)

8 ALPHA-1 ANTITRYPSIN DEFICIENCY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 ALPHA-1 ANTITRYPSIN DEFICIENCY - UNMET NEEDS

10 ALPHA-1 ANTITRYPSIN DEFICIENCY - KEY ENDPOINTS OF TREATMENT

11 ALPHA-1 ANTITRYPSIN DEFICIENCY - MARKETED PRODUCTS

+44 20 8123 2220
info@marketpublishers.com

11.1 List of Alpha-1 Antitrypsin Deficiency Marketed Drugs Across the Top 7 Markets
11.1.1 Prolastin C Liquid (Alpha 1 antitrypsin modified process) - Grifols
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Aralast (Alpha-1 antitrypsin) - Kamada
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Respreeza (Alpha-1 antitrypsin) - CSL Behring
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 ALPHA-1 ANTITRYPSIN DEFICIENCY - PIPELINE DRUGS

12.1 List of Alpha-1 Antitrypsin Deficiency Pipeline Drugs Across the Top 7 Markets
12.1.1 ARO AAT - Arrowhead Pharmaceuticals/Takeda Pharmaceuticals USA
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 INBRX 101 - Inhibrx
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 VX-864 - Vertex Pharmaceuticals
12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Belcesiran - Dicerna Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. ALPHA-1 ANTITRYPSIN DEFICIENCY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. ALPHA-1 ANTITRYPSIN DEFICIENCY – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 ALPHA-1 ANTITRYPSIN DEFICIENCY - MARKET SCENARIO

15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Alpha-1 Antitrypsin Deficiency - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Alpha-1 Antitrypsin Deficiency - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Alpha-1 Antitrypsin Deficiency - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Alpha-1 Antitrypsin Deficiency - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)

+44 20 8123 2220
info@marketpublishers.com

15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Alpha-1 Antitrypsin Deficiency - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Alpha-1 Antitrypsin Deficiency - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Alpha-1 Antitrypsin Deficiency - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Alpha-1 Antitrypsin Deficiency - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Alpha-1 Antitrypsin Deficiency - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Alpha-1 Antitrypsin Deficiency - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Alpha-1 Antitrypsin Deficiency - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Alpha-1 Antitrypsin Deficiency - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Alpha-1 Antitrypsin Deficiency - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Alpha-1 Antitrypsin Deficiency - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Alpha-1 Antitrypsin Deficiency - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Alpha-1 Antitrypsin Deficiency - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Alpha-1 Antitrypsin Deficiency - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Alpha-1 Antitrypsin Deficiency - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Alpha-1 Antitrypsin Deficiency - Market Size by Therapies

+44 20 8123 2220
info@marketpublishers.com

15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Alpha-1 Antitrypsin Deficiency - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Alpha-1 Antitrypsin Deficiency - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Alpha-1 Antitrypsin Deficiency - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Alpha-1 Antitrypsin Deficiency - Access and Reimbursement Overview

16 ALPHA-1 ANTITRYPSIN DEFICIENCY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 ALPHA-1 ANTITRYPSIN DEFICIENCY MARKET - SWOT ANALYSIS

17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 ALPHA-1 ANTITRYPSIN DEFICIENCY MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Alpha-1 Antitrypsin Deficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: https://marketpublishers.com/r/A706494D522CEN.html

Price: US$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/A706494D522CEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

+44 20 8123 2220
info@marketpublishers.com